Search results
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 3 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 2 days agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 2 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 1 day agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 3 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 3 days ago, opens new tab said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 3 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 2 days agoThe firm's stance comes after Pfizer (NYSE:PFE) announced its phase 3 trial for a gene therapy...
WATCH: Organization modifies Valley family's home for free to help kids in wheelchairs
ABC 15 Phoenix· 1 day agoA Valley family is navigating day-to-day life a little easier thanks to a local organization’s...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 3 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...